Back to Journals » OncoTargets and Therapy » Volume 11

Intra-arterial chemotherapy improved survival of stage 2–3 gallbladder cancer after curative resection

Authors Chen C, Feng W, Zheng Y, Bao Y, Feng M

Received 22 February 2018

Accepted for publication 12 April 2018

Published 22 May 2018 Volume 2018:11 Pages 2975—2979

DOI https://doi.org/10.2147/OTT.S166246

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr XuYu Yang


Cheng Chen,1 Wenming Feng,1 Yinyuan Zheng,2 Ying Bao,1 Min Feng1

1Department of General Surgery, First People’s Hospital affiliated to Huzhou Normal College, Huzhou, Zhejiang Province, People’s Republic of China; 2Department of Radiology, First People’s Hospital affiliated to Huzhou Normal College, Huzhou, Zhejiang Province, People’s Republic of China

Objective: To investigate the impact of postresection intra-arterial chemotherapy (IAC) on prognosis of stage 2–3 gallbladder cancer (GBC) after curative resection.
Methods: Between May 2010 and August 2014, 76 cases of GBC accepted curative surgery in our center and were pathologically staged as 2–3. After resection, 37 underwent 4 courses of intravenous chemotherapy (IVC) following 2 courses of IAC (ART group), and 39 received 6 courses of IVC (SYS group). Both the IAC and IVC regimens consisted of oxaliplatin (85 mg/m2) on day 1 and gemcitabine (800 mg/m2) on day 1 and day 8. Chemotherapy-related complications, disease-free survival (DFS), overall survival (OS), and hepatic metastases-free survival (HMFS) were retrospectively analyzed.
Results: Patient characteristics and chemotherapy complications did not differ between the two groups. There was no significant difference in 3-year DFS of the two groups (p=0.0822, HR=0.6270; 95% CI, 0.3627 to 1.0838). The ART group had significantly higher 3-year OS (p=0.0378, HR=0.5460; 95% CI, 0.3025 to 0.9856) and 3-year HMFS (p=0.0414, HR=0.5187; 95% CI, 0.2706 to 0.9940) than the SYS group.
Conclusions: IAC could effectively and safely decrease postresection hepatic metastases and improve 3-year HMFS and OS of stage 2–3 GBC.

Keywords: gallbladder cancer, intra-arterial chemotherapy, hepatic metastases, survival

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]